VivoSim Labs Prices $4M Offering at $1.14 Share Price with 3.95M Warrants
VivoSim Labs priced a $4 million best-efforts offering, raising $3 million in common stock and pre-funded warrants at $1.14 and $1.139 per unit, with a conditional $1 million second tranche due in 30 days. The deal includes 3,947,369 five-year warrants exercisable at $1.71, signaling potential dilution.
1. Offering Terms
VivoSim Labs launched a best-efforts public offering of up to $4 million, closing $3 million initially at $1.14 per share and $1.139 per pre-funded warrant. It issued 286,557 shares, 2,345,022 pre-funded warrants and 3,947,369 five-year warrants at $1.71, with a $1 million second closing in 30 days subject to volume and price conditions.
2. Dilution Impact
The issuance of more than 3.9 million warrants and additional shares creates potential dilution for existing investors if all instruments are exercised. Prefunded warrants carry a $0.001 strike and expire upon exercise, while common warrants offer leverage at a 150% conversion ratio over five years.
3. Strategic Context
Proceeds from the offering will support VivoSim’s development of three-dimensional liver and intestinal NAM models and extend operational runway. The company anticipates accelerated adoption of its human tissue testing methods following FDA refinement of animal testing requirements in April 2025.